FDA warns Flux Lab/The Fluxion over unregistered, unlisted chest binders marketed as medical devices.
What happened
FDA reviewed the website thefluxion.com and found breast binders offered for sale with statements that binding can alleviate gender dysphoria and affect the body, making them devices. FDA also said the company manufactures these devices and its records show no registration or listing for fiscal year 2026.
What FDA found
FDA says the chest binders are medical devices because the website claims they alleviate gender dysphoria or affect body structure or function.
section 201(h) of the Act, 21 U.S.C. § 321(h)FDA says the company did not register as a device manufacturer for fiscal year 2026 as required.
section 510 of the Act, 21 U.S.C. § 360; section 510(p), 21 U.S.C. § 360(p)FDA says the company did not list the devices with FDA as required.
section 510(j) of the Act, 21 U.S.C. § 360(j)FDA says the devices are misbranded (not properly registered or listed) because they were made in an establishment not duly registered and were not included in a required device list.
section 502(o) of the Act, 21 U.S.C. § 352(o)
What FDA wants
FDA asks the company to respond in writing within 15 business days with the specific steps taken, how it will prevent repeat violations, and documentation of corrections or corrective actions, plus a timetable if more time is needed. If the company believes it is not in violation, FDA asks for its reasoning and supporting information.
Who should pay attention
- foreign device manufacturers selling to U.S. consumers
- online sellers of chest binders or compression garments with health claims
- regulatory teams responsible for FDA registration and listing
This is a summary. Read the original letter on fda.gov.